EarlyCDT?-Lung test: improved clinical utility through additional autoantibody assays
详细信息 查看全文
- 作者：Caroline J. Chapman (1)
Graham F. Healey (2)
Andrea Murray (2)
Peter Boyle (3)
Chris Robertson (4)
Laura J. Peek (5)
Jared Allen (1) (2)
Alison J. Thorpe (1)
Geoffrey Hamilton-Fairley (2)
Celine B. Parsy-Kowalska (2)
Isabel K. MacDonald (2)
William Jewell (5)
Paul Maddison (6)
John F. R. Robertson (1) (2) - 关键词：Autoantibodies ; Lung cancer ; Lung cancer diagnosis
- 刊名：Tumor Biology
- 出版年：2012
- 出版时间：October 2012
- 年：2012
- 卷：33
- 期：5
- 页码：1319-1326
- 全文大小：167KB
- 参考文献：1. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, et al. Clinical validation of an AAb test for lung cancer diagnosis. Ann Oncol. 2011;22:383-. CrossRef
2. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, et al. Autoantibodies in lung cancer—possibilities for early detection and subsequent cure. Thorax. 2008;63:228-3. CrossRef
3. Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med. 2011;15:2013-4. CrossRef
4. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001;108:1411-.
5. Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer. 2011;10:33. CrossRef
6. Zhong L, Coe SP, Stromberg AJ, Khatar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006;1:513-. CrossRef
7. Trivers GE, De Benedetti VM, Cawley HL. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996;2:1767-5.
8. Chapman CJ, Robertson JF, Murray A, Titulaer M, Lang B, Thorpe A, et al. The presence of autoantibodies to tumor-associated antigens can predate clinical diagnosis of small cell lung cancer. Chest. 2010;138:775A. CrossRef
9. National Lung Cancer Screeing Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-09. CrossRef
10. Murray A, Chapman CJ, Healey G, Peek LJ, Halsey JF, Parsons G, et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010;21:1687-3. CrossRef
11. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res. 2011;4:1126-4. CrossRef
12. Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, et al. Melanoma-associated antigen genes—an update. Cancer Lett. 2011;302:85-0. CrossRef
13. Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer. 2010;68:105-0. CrossRef
14. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006;28:1089-8.
15. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008;65:3168-1. CrossRef
16. Akamatsu W, Fujihara H, Mitsuhashi T, Yano M, Shibata S, Hayakawa Y, et al. The RNA-binding protein HuD regulates neuronal cell identity and maturation. Proc Natl Acad Sci U S A. 2005;102:4625-0. CrossRef
17. Perrone-Bizzozero N, Bolognani F. Role of HuD and other RNA-binding proteins in neural development and plasticity. J Neurosci Res. 2002;68:121-. CrossRef
18. Graus F, Dalmou J, Re?é R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866-2.
19. Tsou J, Kazarian M, Patel A, Galler JS, Laird-Offringa IA, Carpenter CL, et al. Low level anti-Hu reactivity: a risk marker for small cell lung cancer? Cancer Detect Prev. 2009;32:292-. CrossRef
20. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res. 2011;17:1474-0. CrossRef
21. Parsy CP, Chapman CJ, Barnes AC, Robertson JFR, Murray A. Two-step method to isolate target recombinant protein from co-purified bacterial contaminant SlyD after immobilised metal affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853:314-. CrossRef
22. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715-6. CrossRef
23. Oncimmune. How to assess the risk of lung cancer [Online] Available: http://www.oncimmune.com/physicians-healthcare-professionals/risk-assessment/ [Accessed 09.02.2012].
24. Geyer C. Estimation and optimization functions. In: Gilks WR, Speigelhalter DJ, editors. Markov Chain Monte Carlo in practice. Boca Raton: Chapman and Hall; 1999. p. 241-4.
25. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist. 2001;6:147-2. CrossRef
26. Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002;222:773-1. CrossRef
27. Mathew J, Healey G, Jewell W, Murray A, Chapman C, Peek LJ, et al. Demographics of populations at high risk of lung cancer and results of the / EarlyCDT-Lung test. J Clin Oncol. 2010;28:15s (suppl; abstr 7033). CrossRef
28. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology. 2005;235:259-5. CrossRef - 作者单位：Caroline J. Chapman (1)
Graham F. Healey (2)
Andrea Murray (2)
Peter Boyle (3)
Chris Robertson (4)
Laura J. Peek (5)
Jared Allen (1) (2)
Alison J. Thorpe (1)
Geoffrey Hamilton-Fairley (2)
Celine B. Parsy-Kowalska (2)
Isabel K. MacDonald (2)
William Jewell (5)
Paul Maddison (6)
John F. R. Robertson (1) (2)
1. Centre of Excellence for Autoimmunity in Cancer, The University of Nottingham, Nottingham, UK
2. Oncimmune Ltd, Nottingham City Hospital, Nottingham, UK
3. International Prevention Research Institute (iPRI), Lyon, France
4. Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK
5. Oncimmune USA LLC, De Soto, KS, USA
6. Department of Neurology, Queen’s Medical Centre, Nottingham, UK - ISSN：1423-0380
文摘
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, and the EarlyCDT?-Lung test that measures such AAbs is available as an aid for the early detection of lung cancer in high-risk populations. Improvements in specificity would improve its cost-effectiveness, as well as reduce anxiety associated with false positive tests. Samples from 235 patients with newly diagnosed lung cancer and matched controls were measured for the presence of AAbs to a panel of six (p53, NY-ESO-1, CAGE, GBU4-5, Annexin I, and SOX2) or seven (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) antigens. Data were assessed in relation to cancer type and stage. The sensitivity and specificity of these two panels were also compared in two prospective consecutive series of 776 and 836 individuals at an increased risk of developing lung cancer. The six-AAb panel gave a sensitivity of 39- with a specificity of 89-, while the seven-AAb panel gave a sensitivity of 41- with a specificity of 91- which, once adjusted for occult cancers in the population, resulted in a specificity of 93-. Analysis of these AAb assays in the at-risk population confirmed that the seven-AAb panel resulted in a significant increase in the specificity of the test from 82 to 90-, with no significant change in sensitivity. The change from a six- to a seven-AAb assay can improve the specificity of the test and would result in a PPV of 1 in 8 and an overall accuracy of 92-.